Toulon P, Chadeuf G, Bouillot J L, Amiral J, Cambillau M, Sultan Y, Aiach M
Laboratoire d'Hémostase, Hôpital Broussais, Paris, France.
Eur J Clin Invest. 1991 Jun;21(3):303-9. doi: 10.1111/j.1365-2362.1991.tb01374.x.
Heparin cofactor II is a proteinase inhibitor which inhibits both chymotrypsin and thrombin, and displays great similarities with antithrombin III, the main inhibitor of thrombin in human plasma. Since acute pancreatitis is known to be associated with modification of the proteinase-antiproteinase equilibrium, we studied heparin cofactor II and antithrombin III as well as other biochemical and haematological parameters in 10 patients experiencing attacks of acute pancreatitis. Heparin cofactor II activity decreased during the first week of illness, while its antigen concentration remained subnormal. This discrepancy between antigen concentration and activity which persisted during the first week of illness was due both to complex formation of heparin cofactor II with its target proteinases and to partial proteolysis of the inhibitor. Heparin cofactor II was shown to form a complex with chymotrypsin in the plasma of such patients. Antithrombin III levels remained unchanged throughout the study, with no discrepancy between its activity and antigen concentration. No modification of haemostasis was shown either, except for a rise in the fibrinogen level during the first days of illness. It is concluded that, unlike antithrombin III, heparin cofactor II is involved in the proteinase-inhibitor equilibrium in patients with acute pancreatitis, and that heparin cofactor II might react as an inhibitor of pancreatic proteinases rather than an inhibitor of thrombin.
肝素辅因子II是一种蛋白酶抑制剂,可抑制胰凝乳蛋白酶和凝血酶,与人血浆中凝血酶的主要抑制剂抗凝血酶III有许多相似之处。由于已知急性胰腺炎与蛋白酶-抗蛋白酶平衡的改变有关,我们研究了10例急性胰腺炎发作患者的肝素辅因子II、抗凝血酶III以及其他生化和血液学参数。肝素辅因子II活性在疾病的第一周下降,而其抗原浓度仍低于正常水平。在疾病的第一周持续存在的抗原浓度与活性之间的这种差异,既是由于肝素辅因子II与其靶蛋白酶形成复合物,也是由于抑制剂的部分蛋白水解。已证明肝素辅因子II在此类患者的血浆中与胰凝乳蛋白酶形成复合物。在整个研究过程中,抗凝血酶III水平保持不变,其活性与抗原浓度之间没有差异。除了疾病最初几天纤维蛋白原水平升高外,未显示出血液凝固的改变。结论是,与抗凝血酶III不同,肝素辅因子II参与急性胰腺炎患者的蛋白酶-抑制剂平衡,并且肝素辅因子II可能作为胰腺蛋白酶的抑制剂而非凝血酶的抑制剂起作用。